AbbVie Inc.'s oncology strategy has taken a hit with news of the failure of its investigational PARP inhibitor veliparib in two Phase III studies that tested the drug in combination with chemotherapy in first-line squamous non-small cell lung cancer (NSCLC) and in early stage triple-negative breast cancer.
In one of the trials, the combination treatment failed to improve the overall survival of previously untreated metastatic, squamous NSCLC...